Sign In
Buy VERA
$31.58
-1.31 (-3.98%)
At Close: Aug 10, 2026
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 22'nd Nov 2024
BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted in
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 11'th Nov 2024
Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet
11:00am, Monday, 11'th Nov 2024
The consensus price target hints at a 27.3% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
Vera Therapeutics to Participate at Upcoming Investor Conferences
04:05pm, Friday, 08'th Nov 2024
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Vera Therapeutics to Participate at Upcoming Investor Conferences
08:00am, Friday, 08'th Nov 2024
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
08:21pm, Tuesday, 29'th Oct 2024
BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatment
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
05:37pm, Monday, 28'th Oct 2024
BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatment
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
10:33am, Monday, 28'th Oct 2024
On Saturday, Vera Therapeutics Inc. VERA released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), which showed stabilized kidney function through 96 weeks of
BRISBANE, Calif., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 04'th Oct 2024
BRISBANE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on October 2, 2024, the Compensation Committee granted inducement awards consisting of a
Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
01:45pm, Friday, 04'th Oct 2024
Vera Therapeutics, Inc. topline 36-week data from the phase 3 ORIGIN study, using Atacicept for the treatment of patients with IgA Nephropathy, expected Q2 of 2025. 96-week data from the phase 2 ORIGI
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
06:30am, Wednesday, 02'nd Oct 2024
BRISBANE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
BRISBANE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 10'th Sep 2024
BRISBANE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on September 5, 2024, the Compensation Committee granted inducement awards consisting o
Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says
07:49am, Tuesday, 03'rd Sep 2024
Adobe shares are up 31% over the past three months, having rallied after a strong quarterly earnings report that highlighted strong demand for the software developer's AI products.
